AMRI to Announce Second Quarter Results

ALBANY, N.Y., July 22, 2014 /PRNewswire/ -- AMRI AMRI today announced it will issue second quarter financial results before the opening of the market on Tuesday, August 5, 2014.  Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10:00 a.m. ET.

The conference call can be accessed by dialing 888-505-4375 (domestic calls) or 719-325-2323 (international calls) at 9:50 a.m. ET and entering passcode 9752010.  The audio webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com. 

Replay of the conference call can be accessed by dialing 888-203-1112 (domestic calls) or 719-457-0820 (international calls) and entering passcode 9752010 from Tuesday, August 5, 2014 at 2:00 p.m. ET to Wednesday, August 6, 2014 at 2:00 p.m. ET.  Replay of the audio webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Large Scale Manufacturing (LSM) and Discovery and Development Solutions (DDS). The LSM segment includes Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing, which supports the commercial cGMP manufacturing of complex APIs, starting materials, clinical formulation development and aseptic fill and finish. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI